CancerWorld shared on LinkedIn:
“For decades, RAS was considered undruggable
At ASCO 2026, daraxonrasib challenged that belief, delivering one of the biggest advances ever seen in metastatic pancreatic cancer and earning a standing ovation during the plenary session.
In our exclusive interview, Dr. Alan Sandler explains the science behind the breakthrough, the risks taken to get there, and why he believes
‘This is just the beginning.’
Read the full editorial and Watch the exclusive interview”
Also read ‘The Story Behind One of Radiation Oncology’s Most Influential Companies‘
Other articles about CancerWorld on OncoDaily.